These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 22248505)
1. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Sun J; Wang Z; Luo Y; Tan Y; Allan DS; Huang H Acta Haematol; 2012; 127(3):143-8. PubMed ID: 22248505 [TBL] [Abstract][Full Text] [Related]
2. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy]. Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652 [TBL] [Abstract][Full Text] [Related]
3. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710 [TBL] [Abstract][Full Text] [Related]
4. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951 [TBL] [Abstract][Full Text] [Related]
5. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651 [TBL] [Abstract][Full Text] [Related]
6. [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia]. Huang J; Zou DH; Fu MW; Li ZJ; Xu Y; Zhao YZ; Qi JY; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):673-8. PubMed ID: 22339825 [TBL] [Abstract][Full Text] [Related]
7. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422 [TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Kolb EA; Pan Q; Ladanyi M; Steinherz PG Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284 [TBL] [Abstract][Full Text] [Related]
9. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related]
10. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293 [TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. Liu Z; Liu XL; Du QF; Xu N; Zhong M; Song LL; Yi ZS; Liu QF; Meng FY; Zhou SY Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):512-5. PubMed ID: 19304540 [TBL] [Abstract][Full Text] [Related]
15. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D; Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836 [TBL] [Abstract][Full Text] [Related]
16. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309 [TBL] [Abstract][Full Text] [Related]
17. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase]. Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923 [TBL] [Abstract][Full Text] [Related]
19. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. Medeiros BC; Chun K; Kamel-Reid S; Lipton J Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Fagioli F; Zecca M; Rognoni C; Lanino E; Balduzzi A; Berger M; Messina C; Favre C; Rabusin M; Lo Nigro L; Masetti R; Prete A; Locatelli F; Biol Blood Marrow Transplant; 2012 Jun; 18(6):852-60. PubMed ID: 22019726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]